Charles Schwab
PASG icon

Charles Schwab’s Passage Bio PASG Stock Holding History

Charles Schwab’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,905
Closed -$468K – 3538
2022
Q2 		$468K Sell
9,905
-1,476
-13% -$68.9K ﹤0.01% 3102
2022
Q1 		$706K Sell
11,381
-1,475
-11% -$122K ﹤0.01% 2989
2021
Q4 		$1.63M Buy
12,856
+320
+3% +$52.3K ﹤0.01% 2765
2021
Q3 		$2.5M Buy
12,536
+2,685
+27% +$640K ﹤0.01% 2651
2021
Q2 		$2.61M Buy
9,851
+1,017
+12% +$315K ﹤0.01% 2622
2021
Q1 		$3.09M Buy
8,834
+2,398
+37% +$1.02M ﹤0.01% 2528
2020
Q4 		$3.29M Buy
6,436
+1,285
+25% +$515K ﹤0.01% 2424
2020
Q3 		$1.35M Buy
5,151
+915
+22% +$315K ﹤0.01% 2609
2020
Q2 		$2.32M Buy
+4,236
New +$1.9M ﹤0.01% 2371

Other funds holding PASG

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Charles Schwab's PASG Position: Q3 2022 in Review

Charles Schwab sold out of Passage Bio (PASG) in Q3 2022, closing a stake of 9,905 shares — an estimated $468K sold.

Charles Schwab first reported a position in PASG in Q2 2020 and held it in 9 quarters. The position peaked at $3.29M in Q4 2020. 75 funds tracked by Wall St. Rank hold PASG as of Q3 2022.

  • Charles Schwab reported no remaining Passage Bio position as of Q3 2022 after selling out during the quarter.
  • Charles Schwab sold 9,905 Passage Bio shares in Q3 2022, an estimated $468K.
  • Charles Schwab first reported a position in Passage Bio in Q2 2020 and held it in 9 quarters.
  • Charles Schwab's Passage Bio position peaked at $3.29M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Passage Bio as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.